Hepatocellular Carcinoma

The FDA granted breakthrough device designation to the Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma.

Atezolizumab in combination with bevacizumab delayed time to deterioration of quality of life, physical functioning and role functioning compared with standard-of-care sorafenib as first-line treatment for unresectable hepatocellular carcinoma, according to patient-reported outcomes of the randomized phase 3 IMbrave 150 study scheduled for presentation at Gastrointestinal Cancers Symposium.

The FDA granted orphan drug designation to durvalumab and tremelimumab for treatment of patients with advanced hepatocellular carcinoma.

CStone Pharmaceuticals and Blueprint Medicines Corporation announced the first patient dosed in a phase 1b/2 trial of fisobatinib in combination with CS1001 for the treatment of locally advanced or metastatic hepatocellular carcinoma, according to a press release.

The PAGE-B score and a modified PAGE-B score identified which patients on antiviral therapy for chronic hepatitis B had a low risk for hepatocellular carcinoma development, according to published data.

Increasing care concentration for patients with cirrhosis, which was found to be less than optimal, increased mortality and health care use, according to data published in Clinical Gastroenterology and Liver Disease.

Diets consisting of higher vegetable fat and polyunsaturated fat intake correlated with a lower risk for hepatocellular carcinoma, including cases in which individuals replaced other animal, dairy, or saturated fats with vegetable and polyunsaturated fats, according to data.

The American College of Gastroenterology released a new guideline on disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries, which can lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma.

An ongoing proof-of-concept clinical trial is underway to assess the use of a novel T-cell therapy for the treatment of advanced hepatocellular carcinoma.

Results from the REP 301 and REP 401 studies showed combination therapy with REP2139 and pegylated interferon led to high rates of hepatitis B seroconversion in patients coinfected with hepatitis B and hepatitis D with more than half of treated patients also achieving functional cure of hepatitis D, according to data presented at HEP DART 2019.